VP, Platform Technologies
Shape Therapeutics, United States
Adrian Briggs, Vice President of Platform Technologies at Shape Therapeutics, oversees the technology development of ShapeTX’s gene therapy payload and engineered delivery vehicle platforms. Prior to Shape, Adrian led research teams in CAR-T cell therapy at Juno Therapeutics, Celgene and Bristol-Myers Squibb, focusing on the technologies behind applications from binder discovery to accelerated cell therapy manufacturing. Prior to Juno, Adrian led R&D at AbVitro, building an antibody and T-cell receptor discovery platform acquired by Juno Therapeutics in 2016 for >$125M. Before AbVitro, Adrian performed postdoctoral work in gene editing with George Church lab at Harvard Medical School, and gained his PhD in ancient DNA sequencing, as a core member of the Neandertal Genome Project team with Nobel Prize winner Svante Pääbo in Leipzig, Germany.
Wednesday, May 24, 2023
15:30 – 16:00 CET